GT Biopharma Inc
OXIA
Company Profile
Business description
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Contact
315 Montgomery Street
10th Floor
San FranciscoCA94104
USASector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,777.90 | 50.80 | -0.58% |
| CAC 40 | 7,871.36 | 104.65 | 1.35% |
| DAX 40 | 24,539.68 | 332.77 | 1.37% |
| Dow JONES (US) | 44,440.82 | 200.06 | 0.45% |
| FTSE 100 | 8,864.90 | 10.72 | 0.12% |
| HKSE | 23,892.32 | 255.75 | -1.06% |
| NASDAQ | 20,607.60 | 189.13 | 0.93% |
| Nikkei 225 | 39,821.28 | 132.47 | 0.33% |
| NZX 50 Index | 12,768.61 | 90.41 | -0.70% |
| S&P 500 | 6,261.78 | 36.26 | 0.58% |
| S&P/ASX 200 | 8,538.60 | 52.10 | -0.61% |
| SSE Composite Index | 3,493.05 | 4.43 | -0.13% |